A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

Forbes, Carol; Wilby, Jennifer; Richardson, Gary; Sculpher, Mark; Mather, Lisa; Riemsma, R.P.

doi:10.3310/hta6230

Cited by 16 publications

(17 citation statements)

References 16 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These included the two previous HTA reports that this review updates. 38,39 One of the previous reports was on the use of PLDH 38 and the other on the use of topotecan.…”

Section: Systematic Reviews/meta-analysismentioning

confidence: 99%

“…The first of these reviews was a previous HTA report on the effectiveness of PLDH. 38 The report had included the trial of PLDH versus topotecan included in the present review. 22 The previous report concluded that, overall, there were no statistically significant differences between PLDH and topotecan with regard to the main clinical outcomes.…”

Section: Other Related Systematic Reviewsmentioning

confidence: 99%

“…For the base-case model topotecan acts as a common comparator in both trials (039 and [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49], and therefore the hazard ratio for PLDH and paclitaxel (relative to topotecan) can be obtained directly from the reported trial data. Hence, although there is no direct comparison between PLDH and paclitaxel in trials 039 and 30-49, an indirect comparison can be made between PLDH and paclitaxel in the economic model by applying the HRs associated with each intervention relative to this common baseline.…”

Section: Mixed Treatment Comparison For the Inclusion Of Trial 30-57 mentioning

confidence: 99%

“…For PLDH, survival curves observed in trial 30-49 were obtained from a previous Schering-Plough submission to NICE. 38 Life-years gained were calculated as follows:…”

Section: Summary Of Effectiveness Datamentioning

confidence: 99%

“…Effectiveness evidence was taken from the shortterm results of trial [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] 22 that showed equivalence in outcomes between the two drugs. In addition, results of long-term survival analysis were presented showing a trend favouring PLDH both in terms of overall survival and for a subgroup of platinum-sensitive patients.…”

Section: Overviewmentioning

confidence: 99%

See 4 more Smart Citations

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation

Main

Bojke²,

Griffin³

et al. 2006

Health Technol Assess

104

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

“…These included the two previous HTA reports that this review updates. 38,39 One of the previous reports was on the use of PLDH 38 and the other on the use of topotecan.…”

Section: Systematic Reviews/meta-analysismentioning

confidence: 99%

Section: Other Related Systematic Reviewsmentioning

confidence: 99%

Section: Mixed Treatment Comparison For the Inclusion Of Trial 30-57 mentioning

confidence: 99%

“…For PLDH, survival curves observed in trial 30-49 were obtained from a previous Schering-Plough submission to NICE. 38 Life-years gained were calculated as follows:…”

Section: Summary Of Effectiveness Datamentioning

confidence: 99%

Section: Overviewmentioning

confidence: 99%

See 3 more Smart Citations

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation

Main

Bojke²,

Griffin³

et al. 2006

Health Technol Assess

104

View full text Add to dashboard Cite

show abstract

Development of PEGylated Liposomes

Henderson¹

2011

Drug Delivery in Oncology

View full text Add to dashboard Cite

Review on early technology assessments of nanotechnologies in oncology

2009

View full text Add to dashboard Cite

Nanotechnology is expected to play an increasingly important role in the diagnostics, prognostics, and management of targeted cancer treatments. While papers have described promising results for nanotechnology in experimental settings, the translation of fundamental research into clinical applications has yet to be widely adopted. In future, policy makers will need to anticipate new developments for clinical implementation and introduce technology assessments. Here we present an overview of the literature on the technology assessments that have already been undertaken on early stage nanotechnology in cancer care, with particular emphasis placed on clinical efficacy, efficiency, logistics, patient-related features and technology dynamics.Owing to the current stage of development of most nanotechnologies, we found only a limited number of publications describing the application of either Health Technology Assessment (HTA) or Constructive Technology Assessment (CTA). In spite of the promising conclusions of most papers concerning the benefits of clinical implementation, actual clinically relevant applications were rarely encountered, and so far only a few publications report application of systematic forms of technology assessment. Most articles consider aspects of environmental safety, regulation and ethics, often mentioning the need to investigate such issues more thoroughly. Evaluation of financial and organizational aspects is often missing. In order to obtain a realistic perspective on the translation and implementation process there is a need for a broad and systematic evaluation of nanotechnologies at early stages of development. Assessment methods taking technology dynamics into account, such as Constructive Technology Assessment (CTA) should be considered for evaluation purposes. Published by Elsevier B.V. All rights reserved. IntroductionNanotechnology is a promising technology that is playing an increasingly important role in the diagnostics, prognostics,

show abstract

A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

Cited by 16 publications

References 16 publications

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation

Development of PEGylated Liposomes

Review on early technology assessments of nanotechnologies in oncology

Contact Info

Product

Resources

About